Disruptive Bio Trading ApS: Financial statements 2022
CVR: 41532580
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Disruptive Bio Trading ApS (CVR 41532580) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 100,000,312 and a net result of DKK 7,973,563. The profit margin was 8%. Equity in the 2022 report amounted to DKK 8,774,308. The solvency ratio was 46.5%. The company had 5 employees in the financial year.
- Revenue
- DKK 100,000,312
- Gross Profit
- DKK 14,886,665
- Profit/Loss
- DKK 7,973,563
- Equity
- DKK 8,774,308
- Total Assets
- DKK 18,883,830
- Employees
- 5
Official annual report
Keep an eye on Disruptive Bio Trading ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Disruptive Bio Trading ApS has published its interim report for the period July 14, 2020 to December 31, 2021.
As of April 5, 2022, DLBR REVISION, GODKENDT REVISIONSANPARTSSELSKAB has been appointed auditor of Disruptive Bio Trading ApS.
About Disruptive Bio Trading ApS
Disruptive Bio Trading ApS is a Danish company of the type Anpartsselskab based in Aarhus N, founded in 2020. The company is registered under the industry Ikke-specialiseret engroshandel. The management consists of Nicki Sol Leander Soto. The company is owned by Lily Holding ApS and E.C. Holding ApS. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK 7,990,769 and a net result of DKK 3,813,993 compared with DKK 1,498,942 the year before. Equity in the 2025 report amounted to DKK 4,085,762.